Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $775.94 million. The enterprise value is $400.73 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 60.53 million shares outstanding. The number of shares has increased by 9.82% in one year.
| Current Share Class | 60.53M |
| Shares Outstanding | 60.53M |
| Shares Change (YoY) | +9.82% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 1.33% |
| Owned by Institutions (%) | 77.48% |
| Float | 43.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.25, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.25 |
| Quick Ratio | 10.09 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.02% and return on invested capital (ROIC) is -314.90%.
| Return on Equity (ROE) | -44.02% |
| Return on Assets (ROA) | -28.22% |
| Return on Invested Capital (ROIC) | -314.90% |
| Return on Capital Employed (ROCE) | -58.85% |
| Weighted Average Cost of Capital (WACC) | 3.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.02M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.37% in the last 52 weeks. The beta is -0.11, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +57.37% |
| 50-Day Moving Average | 14.18 |
| 200-Day Moving Average | 10.20 |
| Relative Strength Index (RSI) | 38.80 |
| Average Volume (20 Days) | 713,016 |
Short Selling Information
The latest short interest is 8.11 million, so 13.41% of the outstanding shares have been sold short.
| Short Interest | 8.11M |
| Short Previous Month | 8.39M |
| Short % of Shares Out | 13.41% |
| Short % of Float | 18.78% |
| Short Ratio (days to cover) | 9.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -241.65M |
| Pretax Income | -219.88M |
| Net Income | -219.88M |
| EBITDA | -241.34M |
| EBIT | -241.65M |
| Earnings Per Share (EPS) | -$3.72 |
Full Income StatementBalance Sheet
The company has $377.90 million in cash and $2.68 million in debt, giving a net cash position of $375.21 million or $6.20 per share.
| Cash & Cash Equivalents | 377.90M |
| Total Debt | 2.68M |
| Net Cash | 375.21M |
| Net Cash Per Share | $6.20 |
| Equity (Book Value) | 408.73M |
| Book Value Per Share | 6.78 |
| Working Capital | 349.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$175.75 million and capital expenditures -$49,000, giving a free cash flow of -$175.80 million.
| Operating Cash Flow | -175.75M |
| Capital Expenditures | -49,000 |
| Depreciation & Amortization | 311,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -175.80M |
| FCF Per Share | -$2.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |